JP6133837B2 - Ｃｄ５４発現レポーターシステムを含む免疫細胞の応用および新規なクローン細胞 - Google Patents
Ｃｄ５４発現レポーターシステムを含む免疫細胞の応用および新規なクローン細胞 Download PDFInfo
- Publication number
- JP6133837B2 JP6133837B2 JP2014257422A JP2014257422A JP6133837B2 JP 6133837 B2 JP6133837 B2 JP 6133837B2 JP 2014257422 A JP2014257422 A JP 2014257422A JP 2014257422 A JP2014257422 A JP 2014257422A JP 6133837 B2 JP6133837 B2 JP 6133837B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- cells
- gene
- immune cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims description 95
- 210000002865 immune cell Anatomy 0.000 title claims description 89
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 title claims 7
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 title claims 3
- 238000012360 testing method Methods 0.000 claims description 121
- 239000000126 substance Substances 0.000 claims description 84
- 108700008625 Reporter Genes Proteins 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 52
- 231100000051 skin sensitiser Toxicity 0.000 claims description 27
- 238000004113 cell culture Methods 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 239000005445 natural material Substances 0.000 claims description 5
- 108010060309 Glucuronidase Proteins 0.000 claims description 4
- 231100000121 skin sensitizing Toxicity 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 239000000047 product Substances 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 239000002955 immunomodulating agent Substances 0.000 description 28
- 229940121354 immunomodulator Drugs 0.000 description 28
- 230000002584 immunomodulator Effects 0.000 description 25
- 238000004020 luminiscence type Methods 0.000 description 23
- 108060001084 Luciferase Proteins 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000010261 cell growth Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 15
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 14
- 230000002519 immonomodulatory effect Effects 0.000 description 12
- 239000000411 inducer Substances 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 239000012224 working solution Substances 0.000 description 8
- 108010062580 Concanavalin A Proteins 0.000 description 7
- 229950010131 puromycin Drugs 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 101100167320 Monascus purpureus mpl4 gene Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 231100000489 sensitizer Toxicity 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000013100 final test Methods 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000308 non-sensitiser Toxicity 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150050263 ICAM1 gene Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000004029 environmental poison Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW102147888 | 2013-12-24 | ||
| TW102147888A TWI493036B (zh) | 2013-12-24 | 2013-12-24 | 含一ｃｄ５４表現之報導系統之免疫細胞的應用以及一經選殖之新穎細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015119703A JP2015119703A (ja) | 2015-07-02 |
| JP6133837B2 true JP6133837B2 (ja) | 2017-05-24 |
Family
ID=53454170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014257422A Active JP6133837B2 (ja) | 2013-12-24 | 2014-12-19 | Ｃｄ５４発現レポーターシステムを含む免疫細胞の応用および新規なクローン細胞 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6133837B2 (zh) |
| CN (1) | CN104730072B (zh) |
| TW (1) | TWI493036B (zh) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4689039B2 (ja) * | 1997-12-16 | 2011-05-25 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | ファゴサイトーシスおよびｉｃａｍ−１発現を調節するための組成物および方法 |
| EP1130086A1 (en) * | 2000-02-18 | 2001-09-05 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Genetically engineered keratinocytes and toxicity assay using said keratinocytes |
| US7186864B2 (en) * | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| JP2006311858A (ja) * | 2005-04-05 | 2006-11-16 | Shiseido Co Ltd | 感作性物質のｉｎｖｉｔｒｏ評価方法及びそれに用いる遺伝子工学的に作製された細胞 |
| EP1905843A1 (en) * | 2006-09-29 | 2008-04-02 | Vlaamse Instelling voor Technologisch Onderzoek | Method for determining the allergic potential of a compound |
| KR20100005116A (ko) * | 2007-04-27 | 2010-01-13 | 주식회사 이매진 | 면역 조절제 스크리닝 방법 |
| EP2036989B1 (en) * | 2007-09-12 | 2012-07-25 | Institut Pasteur | Polynucleotide suitable for single cell based reporter assay to monitor gene expression patterns with high spatio-temporal resolution |
| JP5999644B2 (ja) * | 2010-07-01 | 2016-09-28 | 国立大学法人東北大学 | 多色発光細胞を用いた免疫毒性評価システム |
-
2013
- 2013-12-24 TW TW102147888A patent/TWI493036B/zh active
-
2014
- 2014-12-08 CN CN201410740428.XA patent/CN104730072B/zh active Active
- 2014-12-19 JP JP2014257422A patent/JP6133837B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104730072A (zh) | 2015-06-24 |
| TW201525137A (zh) | 2015-07-01 |
| CN104730072B (zh) | 2018-11-27 |
| JP2015119703A (ja) | 2015-07-02 |
| TWI493036B (zh) | 2015-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | The lysosomal Rag-Ragulator complex licenses RIPK1–and caspase-8–mediated pyroptosis by Yersinia | |
| Bahuguna et al. | MTT assay to evaluate the cytotoxic potential of a drug | |
| Liu et al. | Selective advantage of resistant strains at trace levels of antibiotics: a simple and ultrasensitive color test for detection of antibiotics and genotoxic agents | |
| Cevenini et al. | Multicolor bioluminescence boosts malaria research: quantitative dual-color assay and single-cell imaging in Plasmodium falciparum parasites | |
| Canavaci et al. | In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds | |
| Zheng et al. | Nef increases infectivity of HIV via lipid rafts | |
| Blasiak et al. | Genotoxicity of acrylamide in human lymphocytes | |
| Park et al. | Hsp104 overexpression cures Saccharomyces cerevisiae [PSI+] by causing dissolution of the prion seeds | |
| Minear et al. | Curcumin inhibits growth of Saccharomyces cerevisiae through iron chelation | |
| Gao et al. | Exposure to polystyrene microplastics reduces regeneration and growth in planarians | |
| Bellis et al. | Dynamic transcription factor activity profiling in 2D and 3D cell cultures | |
| Connelly et al. | Restructured mitochondrial-nuclear interaction in Plasmodium falciparum dormancy and persister survival after artemisinin exposure | |
| Castro et al. | Rotenone enhances the antifungal properties of staurosporine | |
| Baptiste et al. | Enhanced mitochondrial DNA repair of the common disease-associated variant, Ser326Cys, of hOGG1 through small molecule intervention | |
| Evensen et al. | A novel imaging‐based high‐throughput screening approach to anti‐angiogenic drug discovery | |
| Hong et al. | Discrimination of Avian Influenza Virus Subtypes using Host‐Cell Infection Fingerprinting by a Sulfinate‐based Fluorescence Superoxide Probe | |
| De Magis et al. | BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells | |
| Hodneland Nilsson et al. | A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology | |
| Sharma et al. | In vitro antimalarial activity of novel semisynthetic nocathiacin I antibiotics | |
| Kumar et al. | Protective effect of alpha-tocopherol in deltamethrin induced immunotoxicity | |
| Reader et al. | Streamlined and robust stage-specific profiling of gametocytocidal compounds against Plasmodium falciparum | |
| Nhieu et al. | Targeting Cellular Retinoic Acid binding protein 1 with retinoic acid-like compounds to mitigate Motor Neuron Degeneration | |
| Oh et al. | Assessing Als3 peptide-binding cavity and amyloid-forming region contributions to Candida albicans invasion of human oropharyngeal epithelial cells | |
| Amsri et al. | Adaptation to an amoeba host drives selection of virulence-associated traits and genetic variation in saprotrophic Candida albicans | |
| JP6133837B2 (ja) | Ｃｄ５４発現レポーターシステムを含む免疫細胞の応用および新規なクローン細胞 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151216 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160415 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170302 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170329 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170420 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6133837 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |